Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
UPI's Cash to Debt is ranked higher than
91% of the 392 Companies
in the Global Medical Devices industry.

( Industry Median: 2.71 vs. UPI: No Debt )
UPI' s 10-Year Cash to Debt Range
Min: 1.25   Max: No Debt
Current: No Debt

Equity to Asset 0.73
UPI's Equity to Asset is ranked higher than
78% of the 373 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. UPI: 0.73 )
UPI' s 10-Year Equity to Asset Range
Min: 0.39   Max: 0.91
Current: 0.73

0.39
0.91
Interest Coverage No Debt
UPI's Interest Coverage is ranked higher than
93% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: 81.00 vs. UPI: No Debt )
UPI' s 10-Year Interest Coverage Range
Min: 3.21   Max: 9999.99
Current: No Debt

3.21
9999.99
F-Score: 4
Z-Score: 5.29
M-Score: -3.33
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -21.56
UPI's Operating margin (%) is ranked higher than
54% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 6.50 vs. UPI: -21.56 )
UPI' s 10-Year Operating margin (%) Range
Min: -87.55   Max: 15.27
Current: -21.56

-87.55
15.27
Net-margin (%) -21.78
UPI's Net-margin (%) is ranked higher than
54% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 4.71 vs. UPI: -21.78 )
UPI' s 10-Year Net-margin (%) Range
Min: -73.95   Max: 9.41
Current: -21.78

-73.95
9.41
ROE (%) -40.51
UPI's ROE (%) is ranked higher than
50% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 5.57 vs. UPI: -40.51 )
UPI' s 10-Year ROE (%) Range
Min: -133.34   Max: 23.58
Current: -40.51

-133.34
23.58
ROA (%) -30.94
UPI's ROA (%) is ranked higher than
50% of the 392 Companies
in the Global Medical Devices industry.

( Industry Median: 3.23 vs. UPI: -30.94 )
UPI' s 10-Year ROA (%) Range
Min: -70.97   Max: 14.22
Current: -30.94

-70.97
14.22
ROC (Joel Greenblatt) (%) -356.12
UPI's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 391 Companies
in the Global Medical Devices industry.

( Industry Median: 12.89 vs. UPI: -356.12 )
UPI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -494.76   Max: 48.21
Current: -356.12

-494.76
48.21
Revenue Growth (%) 16.70
UPI's Revenue Growth (%) is ranked higher than
92% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. UPI: 16.70 )
UPI' s 10-Year Revenue Growth (%) Range
Min: -23.7   Max: 16.7
Current: 16.7

-23.7
16.7
EBITDA Growth (%) 6.60
UPI's EBITDA Growth (%) is ranked higher than
82% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: -2.90 vs. UPI: 6.60 )
UPI' s 10-Year EBITDA Growth (%) Range
Min: -38.3   Max: 214.1
Current: 6.6

-38.3
214.1
» UPI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

UPI Guru Trades in Q3 2013

Jim Simons 73,000 sh (+54.33%)
» More
Q4 2013

UPI Guru Trades in Q4 2013

Jim Simons 78,100 sh (+6.99%)
» More
Q1 2014

UPI Guru Trades in Q1 2014

Jim Simons 91,300 sh (+16.9%)
» More
Q2 2014

UPI Guru Trades in Q2 2014

Jim Simons 123,178 sh (+34.92%)
» More
» Details

Insider Trades

Latest Guru Trades with UPI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.08
UPI's P/B is ranked lower than
55% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 3.50 vs. UPI: 5.08 )
UPI' s 10-Year P/B Range
Min: 0.44   Max: 11.07
Current: 5.08

0.44
11.07
P/S 2.24
UPI's P/S is ranked higher than
69% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 3.21 vs. UPI: 2.24 )
UPI' s 10-Year P/S Range
Min: 0.38   Max: 11.49
Current: 2.24

0.38
11.49
EV-to-EBIT -8.12
UPI's EV-to-EBIT is ranked higher than
51% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 57.01 vs. UPI: -8.12 )
UPI' s 10-Year EV-to-EBIT Range
Min: 103   Max: 355.9
Current: -8.12

103
355.9
Current Ratio 4.11
UPI's Current Ratio is ranked higher than
80% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 2.86 vs. UPI: 4.11 )
UPI' s 10-Year Current Ratio Range
Min: 1.72   Max: 13.51
Current: 4.11

1.72
13.51
Quick Ratio 3.94
UPI's Quick Ratio is ranked higher than
86% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 2.12 vs. UPI: 3.94 )
UPI' s 10-Year Quick Ratio Range
Min: 1.34   Max: 13.24
Current: 3.94

1.34
13.24

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.10
UPI's Price/Net Cash is ranked higher than
94% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. UPI: 9.10 )
UPI' s 10-Year Price/Net Cash Range
Min: 1.81   Max: 107.2
Current: 9.1

1.81
107.2
Price/Net Current Asset Value 6.77
UPI's Price/Net Current Asset Value is ranked higher than
92% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. UPI: 6.77 )
UPI' s 10-Year Price/Net Current Asset Value Range
Min: 1.32   Max: 20.79
Current: 6.77

1.32
20.79
Price/Tangible Book 5.17
UPI's Price/Tangible Book is ranked higher than
70% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 6.09 vs. UPI: 5.17 )
UPI' s 10-Year Price/Tangible Book Range
Min: 0.76   Max: 12.77
Current: 5.17

0.76
12.77
Price/Median PS Value 0.74
UPI's Price/Median PS Value is ranked higher than
91% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 1.15 vs. UPI: 0.74 )
UPI' s 10-Year Price/Median PS Value Range
Min: 0.14   Max: 4.73
Current: 0.74

0.14
4.73
Forward Rate of Return (Yacktman) -1.30
UPI's Forward Rate of Return (Yacktman) is ranked higher than
70% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 1.43 vs. UPI: -1.30 )
UPI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.1   Max: 37.4
Current: -1.3

0.1
37.4

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Uroplasty, Inc. was incorporated in January 1992 as a Minnesota Corporation and a wholly owned subsidiary of its original parent. In February 1995, it became a stand-alone, privately held company to a Plan of Reorganization confirmed by the U.S. Bankruptcy Court. It is a medical device Company that develops, manufactures and markets innovative, proprietary products for the treatment of voiding dysfunctions. The Company focuses on two products: Urgent PC system, which is the only FDA-approved minimally-invasive, office-based neurostimulation therapy for the treatment of urinary urgency, urinary frequency, and urge incontinence - symptoms often associated with overactive bladder (OAB); and Macroplastique, a urethral bulking agent for the treatment of adult female stress urinary incontinence mainly due to intrinsic sphincter deficiency (ISD). The physicians prefer its products because they offer an effective therapy for the patient, could be administered in office-based settings and, to the extent reimbursement are in place, provide the physicians a new profitable recurring revenue stream. The patients prefer its products because they are minimally invasive treatment alternatives and neither have the side effects associated with pharmaceutical treatment options nor the morbidity associated with surgery. The Company has a U.S. Food and Drug Administration (FDA)-qualified manufacturing facility in Minnetonka, Minnesota. It uses only medical grade solid silicone material in its tissue bulking products and do not use semi-liquid silicone gel, as was used in breast implants. Competitors offer management and curative treatments, including neurostimulation devices, tissue bulking agents and urethral sling products. The Company has registered Uroplasty, Macroplastique, VOX, PTQ and Bioplastique as trademarks with the U.S. Patent and Trademark Office and throughout the European Union. The testing, manufacturing, promotion, marketing and distribution of its products in the United States, Europe and other parts of the world are subject to regulation by numerous governmental authorities, including the FDA, the European Union and other analogous agencies.
» More Articles for UPI

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight Sep 02 2013 
Uroplasty Inc Reports Operating Results (10-K/A) Feb 22 2011 
Uroplasty Inc (UPI) COO Susan Hartjes Holman sells 12,000 Shares Feb 04 2011 
Uroplasty Inc Reports Operating Results (10-Q) Jan 27 2011 
Uroplasty Inc Reports Operating Results (10-Q) Oct 27 2010 
Uroplasty Inc Reports Operating Results (10-K/A) Jun 18 2010 
Uroplasty Inc Reports Operating Results (10-Q) Feb 01 2010 
Uroplasty Inc Reports Operating Results (10-Q) Nov 02 2009 
Uroplasty Inc Reports Operating Results (10-Q) Aug 04 2009 
Uroplasty Reports First Fiscal Quarter Results Aug 03 2009 

More From Other Websites
UROPLASTY INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Aug 22 2014
National Government Services Issues Positive Coverage for Percutaneous Tibial Nerve Stimulation Aug 11 2014
National Government Services Issues Positive Coverage for Percutaneous Tibial Nerve Stimulation Aug 11 2014
UROPLASTY INC Financials Aug 09 2014
Uroplasty To Participate In Canaccord Genuity 34th Annual Growth Conference Aug 06 2014
Uroplasty To Participate In Canaccord Genuity 34th Annual Growth Conference Aug 06 2014
UROPLASTY INC Files SEC form 10-Q, Quarterly Report Jul 31 2014
Uroplasty Inc Earnings Call scheduled for 4:30 pm ET today Jul 24 2014
UROPLASTY INC Files SEC form 8-K, Results of Operations and Financial Condition Jul 24 2014
Uroplasty Reports Fiscal First Quarter Results Jul 24 2014
Q1 2015 Uroplasty, Inc. Earnings Release - After Market Close Jul 24 2014
Uroplasty To Announce First Quarter Fiscal Year 2015 Financial Results On July 24, 2014 Jul 10 2014
AUA/SUFU Validate Peripheral Tibial Nerve Stimulation (PTNS) For The Treatment Of Overactive Bladder... Jun 30 2014
Uroplasty To Participate In JMP Securities Healthcare Conference Jun 16 2014
UROPLASTY INC Files SEC form 10-K, Annual Report Jun 09 2014
UROPLASTY INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Jun 03 2014
UROPLASTY INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Jun 02 2014
Uroplasty Strengthens Board of Directors with Addition of Kevin H. Roche Jun 02 2014
UROPLASTY INC Files SEC form 8-K, Change in Directors or Principal Officers May 28 2014
UROPLASTY INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... May 21 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK